palmitoylethanolamide.com.au
HomeResearchMarichal-Cancino 2020

Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats

Marichal-Cancino BA, Gonzalez-Hernandez A, MaassenVanDenBrink A, Ramirez-San Juan E, Villalon CM. J Vasc Res. 2020;57(3):152-163.

Laboratory studyOther animals

Design
Laboratory study
Subjects
Wistar pithed rats
Dose used in the study
PEA, 0.1 to 3.1 micrograms/kg/min, continuous intravenous infusion, with or without receptor antagonists (NIDA41020, AM630, capsazepine, cannabidiol)
Duration
Not stated in the abstract
What was measured
Vasopressor responses to sympathetic stimulation or noradrenaline, and resting blood pressure, with and without CB1, CB2, TRPV1 and GPR55 antagonists

What the authors reported

PEA dose-dependently inhibited vasopressor responses to sympathetic stimulation and noradrenaline, and lowered resting blood pressure. These effects were partly blocked by the CB1, TRPV1 or GPR55 antagonists individually, unaffected by the CB2 antagonist, and abolished when all three antagonists were combined.

Limits of this study

A rat pharmacology study; it cannot show effect in people. Funding and conflicts not stated in the abstract.

Source

PubMed 32248195 · doi:10.1159/000506158

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.